VEZAAR TABLETS

(Losartan Potassium 25 mg & 50 mg)

COMPOSITION

Vezaar 25 mg: Each tablet contains Losartan Potassium 25 mg.
Vezaar 50 mg: Each tablet contains Losartan Potassium 50 mg.
Excipients: as per approved formulation.

DESCRIPTION & PHARMACOLOGY

Losartan is an angiotensin II receptor blocker (ARB). It selectively blocks angiotensin II binding to AT1 receptors, reducing vasoconstriction and aldosterone secretion, thereby lowering blood pressure. Its active metabolite also contributes to the antihypertensive effect.

INDICATIONS

Treatment of hypertension in adults and children aged 6 years and older; reduction of stroke risk in selected patients with hypertension and left ventricular hypertrophy; treatment of diabetic nephropathy in selected adults with type 2 diabetes, hypertension and proteinuria, subject to approved labeling.

DOSAGE & ADMINISTRATION

Adults with hypertension: usual starting dose 50 mg once daily. Some patients, including those with possible intravascular volume depletion or hepatic impairment, may require a 25 mg starting dose. Dose may be increased to 100 mg once daily based on response and tolerability.

DOSAGE IN SPECIFIC CONDITIONS

For hypertensive patients with left ventricular hypertrophy or diabetic nephropathy, the usual starting dose is 50 mg once daily; adjustment to 100 mg once daily or addition of other therapy may be needed under medical supervision.

PAEDIATRIC USE

For hypertension in children aged 6 years and older, usual starting dose is 0.7 mg/kg once daily (up to 50 mg); dose adjustment is based on blood pressure. Not recommended in children younger than 6 years or with markedly impaired renal function. Use appropriate formulation for calculated dose.

ADMINISTRATION

Take orally with or without food, preferably at the same time each day. Continue as prescribed even when blood pressure is controlled. Do not change strength or stop treatment without medical advice.

CONTRAINDICATIONS

Hypersensitivity to losartan or any excipient. Concomitant aliskiren use in patients with diabetes is contraindicated.

PREGNANCY WARNING

WARNING: FETAL TOXICITY. Drugs acting on the renin-angiotensin system may cause injury or death to the developing fetus. Discontinue losartan as soon as pregnancy is detected and contact a physician immediately. Avoid use during pregnancy.

WARNINGS & PRECAUTIONS

Symptomatic hypotension can occur in salt- or volume-depleted patients, especially after diuretic therapy. Correct depletion where possible and monitor blood pressure. Monitor kidney function and serum potassium in at-risk patients.

Renal impairment, renal artery stenosis, heart failure or concomitant medicines affecting kidney function may increase risk of acute kidney injury. Hyperkalaemia may occur, particularly in patients with renal impairment or using potassium-raising medicines.

DRUG INTERACTIONS

Potassium supplements, potassium-containing salt substitutes and potassium-sparing diuretics may increase potassium levels. NSAIDs (including selective COX-2 inhibitors) can reduce antihypertensive effect and worsen kidney function. Lithium concentrations may rise; monitor if coadministered.

Combining losartan with ACE inhibitors, aliskiren or other renin-angiotensin system blockers increases risks of hypotension, hyperkalaemia and renal impairment; avoid dual blockade unless specifically justified and monitored.

ADVERSE REACTIONS

Reported reactions include dizziness, hypotension, upper respiratory infection, nasal congestion, back pain, fatigue and increased potassium. Rare serious reactions include angioedema, renal dysfunction and severe allergic reactions.

OVERDOSAGE

Overdose may cause marked hypotension and changes in heart rate. Seek emergency care. Treatment is supportive with blood pressure, electrolyte and renal function monitoring. Losartan and its active metabolite are not readily removed by haemodialysis.

BREASTFEEDING

There are insufficient human lactation data. A clinician should assess the need for treatment and potential infant risk; an alternative medicine may be preferred, especially when nursing a newborn.

STORAGE CONDITIONS

Store according to the approved product storage specification, protected from excessive heat, moisture and light. Keep out of reach of children. Do not use after expiry.

PRESENTATION

Vezaar Tablets 25 mg: 2 x 10 tablets (20 tablets).
Vezaar Tablets 50 mg: 2 x 10 tablets (20 tablets).

PATIENT ADVICE

Monitor blood pressure as advised. Avoid potassium-containing salt substitutes unless approved by your physician. Report fainting, facial swelling, reduced urination or pregnancy immediately. Do not double a missed dose.

THERAPEUTIC CLASS

Angiotensin II receptor blocker (ARB); antihypertensive. Primary segments: Cardiology and Internal Medicine; secondary: Nephrology and Diabetes care.

MANUFACTURED BY

Vega Pharmaceuticals (Pvt.) Ltd.